article thumbnail

Building a digital therapeutic for paediatric behavioural health – the pharmaphorum podcast

pharmaphorum

More broadly, Benny and Jonah look at some of the challenges still facing digital therapeutics in the market today, including the difficulty of securing reimbursement for these products, despite interest from providers, patients, and the health system as a whole.

article thumbnail

Sanofi forges $30m alliance with digital health firm DarioHealth

pharmaphorum

DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. Erez Raphael.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Digital health player UpHealth swells with three-way merger

pharmaphorum

The combined company will cover a broad swathe of the digital health landscape, bringing together population health software, telehealth services, digital pharmacy delivering compounded and manufactured medicines, and tech enabled behavioural health services for people with mental health and substance abuse issues.

article thumbnail

Ohio is third state to fund Pear’s digital therapeutics to tackle addiction

pharmaphorum

The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017. Pear noted that the grant comes at a time when many communities are seeing increased demand for behavioural health and recovery services amid the ongoing coronavirus pandemic.

article thumbnail

Pear extends digital therapeutics partnership with Spero

pharmaphorum

“We believe having access to patient-reported data via Pear’s clinician dashboard gives us better insight into patient behaviours.”. Pear is also working with other addiction specialists, including Florida-based Cove Behavioural Health, and provides its DTx to a number of state health programmes.

article thumbnail

FDA green lights Oxehealth vital signs monitoring software

pharmaphorum

The FDA’s approval under the de novo classification framework for medical devices that are likely to be safe and effective for their intended use, but for which there are no similar devices already available on the market. The approval means the Oxford University spin-out can place Oxevision on the market in all US states.

Nurses 59
article thumbnail

Amwell dials in deals worth $320m to buy two digital health players

pharmaphorum

US telehealth group Amwell has agreed to buy two digital health specialists – SilverCloud Health and Conversa Health – as it looks to expand its services amid a boom in virtual healthcare delivery.